Yale Spinout Success Snapshot - NextCure
- Lieping Chen is the United Technologies Corporation Professor in Cancer Research and the pioneer of Immuno-checkpoint modulators (Opdivo of BMS and Keytruda of Merck).
- He founded NextCure to develop new cancer drugs.
- Raised a record $67M Series A funding
- In Nov. 2018, announced the completion of a $93million series B equity financing.
- NextCure is now a publicly traded company since its IPO in May of 2019